18 June 2021 - Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging next year could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen treatment without clear evidence that it works.

In approving Biogen’s Aduhelm over the objection of its own panel of outside expert advisers, the U.S. FDA has required a trial to confirm that the medicine will indeed slow progression of the lethal, mind-wasting disease - a process that could take several years - even as the drug is being used by patients.

Read Reuters article